GCGR agonism has consequently been identified as a possible therapeutic target for obesity, and a number of studies have investigated the effects of acute glucagon administration on energy intake and energy expenditure in humans. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.